Cargando…
Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
In mucopolysaccharidoses (MPS), glycosaminoglycans (GAG) accumulate in tissues. In MPS II, approximately two-thirds of patients are cognitively impaired. We investigated levels of GAG in cerebrospinal fluid (CSF) in different populations from four clinical studies (including NCT00920647 and NCT01449...
Autores principales: | Hendriksz, Christian J., Muenzer, Joseph, Vanderver, Adeline, Davis, Jonathan M., Burton, Barbara K., Mendelsohn, Nancy J., Wang, Nan, Pan, Luying, Pano, Arian, Barbier, Ann J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471392/ https://www.ncbi.nlm.nih.gov/pubmed/28649553 http://dx.doi.org/10.1016/j.ymgmr.2015.11.001 |
Ejemplares similares
-
Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015) -
Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020) -
The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019) -
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
por: Muenzer, Joseph, et al.
Publicado: (2017) -
Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid
por: Fogh, Jens Rose, et al.
Publicado: (2020)